Loading
CAR-T Cell Therapy Research / Virus-based Gene Therapy Research / CRISPR and Genetic Engineering · Journal article
Cancer Science · August 19, 2026
Early or partial results. Treat as a signal, not a conclusion.
This work describes development and optimization of a CRISPR-based T-Editor platform for genetic engineering of tumor-infiltrating lymphocytes, identifying FAM84B as a candidate target. FAM84B base-edited TIL showed enhanced cytolytic activity and improved antitumor efficacy in patient-derived xenograft models compared to non-engineered control TIL. Clinical translation and efficacy in human patients remain to be established.
Preclinical proof-of-concept and patient-derived xenograft study. Patient-derived tumor-infiltrating lymphocytes and patient-derived xenograft models; no human subjects.. Intervention: T-Editor platform with cytosine base editing targeting FAM84B in tumor-infiltrating lymphocytes.. Compared with: Non-engineered control TIL and Cas9-knockout TIL..
FAM84B emerged as the top candidate target with the most pronounced enhancement of TIL cytolytic activity upon knockout. Cytosine base editing of FAM84B achieved high editing efficiency with minimal insertion–deletion (indel) events. FAM84B-edited TIL displayed increased CD62L+ memory subset, enhanced effector function and cytolytic activity, and improved in vivo antitumor efficacy compared with non-engineered control TIL in PDX models.
Long-term safety of base-edited TIL, durability of response, or persistence in vivo not reported.
This represents an early-stage approach to enhancing TIL therapy through genetic modification. While promising for future clinical development, the work does not yet establish whether FAM84B editing improves patient outcomes or can be safely translated to the clinic.
Early-stage mechanistic work demonstrating proof-of-concept for a gene-editing platform in preclinical and PDX models, without human clinical efficacy data or direct comparison to standard TIL therapy.
As stated by the source record.
This represents an early-stage approach to enhancing TIL therapy through genetic modification. While promising for future clinical development, the work does not yet establish whether FAM84B editing improves patient outcomes or can be safely translated to the clinic.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
ABSTRACT Tumor‐infiltrating lymphocytes (TIL) therapy has demonstrated clinical potential in malignancies. However, limited understanding of why only a subset of patients respond to TIL therapy, coupled with the lack of simple and efficient methods to genetically engineer fragile TIL, has hindered efforts to enhance TIL efficacy through genetic modification. A T‐Editor platform enabling rapid and efficient CRISPR‐mediated gene editing in TIL was developed and optimized. To minimize the risk of chromosomal translocations associated with Cas9‐induced double‐strand breaks (DSBs), single‐guide RNAs (sgRNAs) were designed for cytosine base editing (CBE). The expansion capacity, phenotypic profile, cytokine production, and in vitro cytolytic activity of base‐edited TIL were compared with those of Cas9‐KO TIL. In vivo efficacy was assessed using patient‐derived xenograft (PDX) mouse models. The T‐Editor platform was optimized for TIL gene editing by refining stimulation conditions, electroporation parameters, and CRISPR/Cas9 reagent dosing. FAM84B emerged as the top candidate, with its knockout resulting in the most pronounced enhancement of TIL cytolytic activity. CBE‐mediated C·G‐to‐T·A conversion in the FAM84B exon achieved high editing efficiency with minimal insertion–deletion (indel) events. Base‐edited TIL exhibited comparable expansion, phenotype, cytokine production, and in vitro cytolytic activity relative to Cas9‐KO TIL. Compared with non‐engineered control TIL, FAM84B‐edited TIL displayed an increased CD62L + memory subset, enhanced effector function and cytolytic activity, and improved in vivo antitumor efficacy. In conclusion, the T‐Editor platform enables rapid and efficient CRISPR‐mediated gene editing for engineering TIL to enhance its therapeutic potency. FAM84B may represent a novel potential target for improving TIL‐mediated antitumor activity.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.